Northern Trust Corp Sells 16,173 Shares of Kymera Therapeutics, Inc. $KYMR

Key Points

• Northern Trust Corp reduced its stake in Kymera Therapeutics by 3.7%, now holding 421,660 shares valued at approximately $11.54 million.
• Director Bros. Advisors LP Baker made a significant purchase of 655,500 shares at $44.00 each, increasing their ownership by 12% to a total of 6,117,295 shares.
• Analysts have mixed views on Kymera Therapeutics, with a consensus rating of "Buy", and price targets ranging from $55.00 to $72.00 per share.

Northern Trust Corp trimmed its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 3.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 421,660 shares of the company's stock after selling 16,173 shares during the quarter. Northern Trust Corp owned about 0.65% of Kymera Therapeutics worth $11,541,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. Ameriprise Financial Inc. acquired a new position in shares of Kymera Therapeutics during the fourth quarter valued at about $344,000. GAMMA Investing LLC raised its position in Kymera Therapeutics by 3,851.5% in the first quarter. GAMMA Investing LLC now owns 6,678 shares of the company's stock worth $183,000 after acquiring an additional 6,509 shares during the period. Millennium Management LLC raised its position in Kymera Therapeutics by 205.0% in the fourth quarter. Millennium Management LLC now owns 115,918 shares of the company's stock worth $4,663,000 after acquiring an additional 77,912 shares during the period. Rhumbline Advisers raised its position in shares of Kymera Therapeutics by 9.0% in the first quarter. Rhumbline Advisers now owns 69,928 shares of the company's stock valued at $1,914,000 after purchasing an additional 5,771 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Kymera Therapeutics by 7.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,960 shares of the company's stock valued at $1,163,000 after acquiring an additional 2,011 shares in the last quarter.

Kymera Therapeutics Stock Down 0.4%

Shares of Kymera Therapeutics stock traded down $0.17 during trading on Wednesday, reaching $43.32. The company's stock had a trading volume of 53,750 shares, compared to its average volume of 733,763. Kymera Therapeutics, Inc. has a 52-week low of $19.44 and a 52-week high of $53.27. The company has a market cap of $3.10 billion, a price-to-earnings ratio of -12.48 and a beta of 2.17. The firm's 50-day moving average is $43.35 and its two-hundred day moving average is $37.07.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 31.60%. The business had revenue of $11.48 million during the quarter, compared to analysts' expectations of $17.37 million. During the same period last year, the company posted ($0.58) EPS. Kymera Therapeutics's revenue for the quarter was down 55.1% on a year-over-year basis. On average, equities research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Insiders Place Their Bets

In other news, Director Bros. Advisors Lp Baker purchased 655,500 shares of the stock in a transaction that occurred on Monday, June 30th. The stock was bought at an average cost of $44.00 per share, for a total transaction of $28,842,000.00. Following the acquisition, the director directly owned 6,117,295 shares of the company's stock, valued at $269,160,980. This represents a 12.00% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bvf Partners L. P/Il purchased 317,167 shares of the stock in a transaction that occurred on Monday, June 30th. The shares were purchased at an average price of $44.00 per share, with a total value of $13,955,348.00. Following the completion of the acquisition, the director directly owned 2,798,795 shares in the company, valued at $123,146,980. The trade was a 12.78% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 16.01% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on KYMR shares. Wall Street Zen cut shares of Kymera Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. UBS Group cut their price target on shares of Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. BTIG Research reissued a "buy" rating and issued a $59.00 price target on shares of Kymera Therapeutics in a research note on Thursday, June 26th. Stifel Nicolaus started coverage on shares of Kymera Therapeutics in a research note on Tuesday, May 20th. They issued a "buy" rating and a $55.00 price target for the company. Finally, Bank of America raised shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price target for the company in a research note on Monday, June 2nd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Kymera Therapeutics presently has an average rating of "Buy" and an average target price of $58.76.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.